Ensign Peak Advisors’s Cytokinetics CYTK Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.74M | Buy |
203,946
+172,150
| +541% | +$5.69M | 0.01% | 575 |
|
|
2025
Q1 | $1.28M | Sell |
31,796
-265,039
| -89% | -$10.7M | ﹤0.01% | 1114 |
|
|
2024
Q4 | $14M | Sell |
296,835
-165,001
| -36% | -$7.76M | 0.02% | 388 |
|
|
2024
Q3 | $24.4M | Sell |
461,836
-1,595
| -0.3% | -$84.2K | 0.04% | 289 |
|
|
2024
Q2 | $25.1M | Buy |
463,431
+39,172
| +9% | +$2.12M | 0.05% | 271 |
|
|
2024
Q1 | $29.7M | Sell |
424,259
-1,604
| -0.4% | -$112K | 0.05% | 253 |
|
|
2023
Q4 | $35.6M | Hold |
425,863
| – | – | 0.07% | 231 |
|
|
2023
Q3 | $12.5M | Buy |
425,863
+74,694
| +21% | +$2.2M | 0.03% | 336 |
|
|
2023
Q2 | $11.5M | Hold |
351,169
| – | – | 0.02% | 387 |
|
|
2023
Q1 | $12.4M | Buy |
351,169
+8,400
| +2% | +$296K | 0.03% | 369 |
|
|
2022
Q4 | $15.7M | Buy |
342,769
+59,400
| +21% | +$2.72M | 0.04% | 332 |
|
|
2022
Q3 | $13.7M | Buy |
283,369
+45,600
| +19% | +$2.21M | 0.03% | 321 |
|
|
2022
Q2 | $9.34M | Buy |
237,769
+69,904
| +42% | +$2.75M | 0.02% | 396 |
|
|
2022
Q1 | $6.18M | Buy |
167,865
+9,960
| +6% | +$367K | 0.01% | 528 |
|
|
2021
Q4 | $7.2M | Sell |
157,905
-40,650
| -20% | -$1.85M | 0.01% | 560 |
|
|
2021
Q3 | $7.1M | Sell |
198,555
-4,000
| -2% | -$143K | 0.01% | 519 |
|
|
2021
Q2 | $4.01M | Buy |
202,555
+37,010
| +22% | +$733K | 0.01% | 740 |
|
|
2021
Q1 | $3.85M | Buy |
165,545
+91,145
| +123% | +$2.12M | 0.01% | 743 |
|
|
2020
Q4 | $1.55M | Sell |
74,400
-49,022
| -40% | -$1.02M | ﹤0.01% | 1203 |
|
|
2020
Q3 | $2.67M | Buy |
123,422
+49,022
| +66% | +$1.06M | 0.01% | 822 |
|
|
2020
Q2 | $1.75M | Hold |
74,400
| – | – | ﹤0.01% | 1044 |
|
|
2020
Q1 | $877K | Buy |
74,400
+8,500
| +13% | +$100K | ﹤0.01% | 1216 |
|
|
2019
Q4 | $699K | Buy |
+65,900
| New | +$699K | ﹤0.01% | 1456 |
|